US 12,233,184 B2
Dimethylacrylamide (DMAA) hydrogel for expansion microscopy (ExM)
Edward Stuart Boyden, Chestnut Hill, MA (US); Nikita Obidin, Somerville, MA (US); Ruixuan Gao, Cambridge, MA (US); and Linyi Gao, Cambridge, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Jan. 8, 2021, as Appl. No. 17/144,551.
Application 17/144,551 is a continuation of application No. PCT/US2018/041930, filed on Jul. 13, 2018.
Prior Publication US 2021/0196856 A1, Jul. 1, 2021
Int. Cl. B01L 3/00 (2006.01); A61L 27/16 (2006.01); A61L 27/56 (2006.01); B01F 23/00 (2022.01); B01F 23/41 (2022.01); B01F 101/23 (2022.01); B01L 9/00 (2006.01); B23Q 17/24 (2006.01); C07K 14/705 (2006.01); C08F 220/56 (2006.01); C08L 33/26 (2006.01); C12M 1/34 (2006.01); C12Q 1/04 (2006.01); C12Q 1/18 (2006.01); C12Q 1/686 (2018.01); G01N 1/31 (2006.01); G01N 21/17 (2006.01); G01N 21/3577 (2014.01); G01N 21/359 (2014.01); G01N 21/39 (2006.01); G01N 21/45 (2006.01); G01N 21/64 (2006.01); G01N 21/77 (2006.01); G01N 21/78 (2006.01); G01N 27/414 (2006.01); G01N 30/12 (2006.01); G01N 30/68 (2006.01); G01N 30/70 (2006.01); G01N 30/72 (2006.01); G01N 30/88 (2006.01); G01N 33/00 (2006.01); G01N 33/18 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01); G01N 33/68 (2006.01); G01N 33/74 (2006.01); G01N 35/00 (2006.01); G01N 35/10 (2006.01); G06T 7/00 (2017.01); G06T 7/90 (2017.01); H10K 10/46 (2023.01); H10K 85/00 (2023.01); H10K 85/20 (2023.01)
CPC A61L 27/16 (2013.01) [A61L 27/56 (2013.01); C08F 220/56 (2013.01); C08L 33/26 (2013.01); G01N 1/312 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A method for preparing an expandable tissue sample, the method comprising the steps of:
(a) incubating a tissue sample with a composition comprising:
precursors of a polymer, the precursors comprising linear monomers at a concentration of about 20 to about 50 wt %, wherein the linear monomers comprise acrylamide, dimethylacrylamide, and sodium acrylate, and wherein the sodium acrylate is about 10 to about 25 mol % of the linear monomers,
about 0.1 to about 1.0 mol % polymerization initiator,
about 0.005 to about 0.02 wt % polymerization inhibitor, and
about 0.001 to about 0.01 wt % polymerization accelerator,
wherein the composition does not include a separate crosslinker from the dimethylacrylamide; and
(b) polymerizing the composition within the tissue sample to form a polymer, wherein the polymer is embedded throughout the tissue sample.